Biotech Archives - Page 106 of 795

2 minute read

Calibr-Skaggs Announces Expansion Of Option And License Agreement With AbbVie To Develop Novel Cell Therapies; AbbVie Will Pay Calibr-Skaggs An Upfront License Fee And Maintain Exclusive Access To Their Switchable Car-T Platform For A Term Of Upto 5-Ye…

February 6, 1:04 PM

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVieAbbVie also has the option to explore the

ABBV

2 minute read

Vertex Pharmaceuticals’ Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients

By Vandana Singh

February 6, 10:57 AM

Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety.

VRTX

1 minute read

Zynex Receives FDA Clearance For Its Next Generation M-Wave Neuromuscular Electrical Stimulation Device

By Benzinga Newsdesk

February 6, 10:16 AM

Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today

ZYXI

2 minute read

Cognition Therapeutics Announces New Publication Identifying Key Proteins Involved In Amyloid Oligomer Binding And Supports Mechanism Of CT1812

By Benzinga Newsdesk

February 6, 9:48 AM

Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in

CGTX

2 minute read

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B

By Vandana Singh

February 6, 9:46 AM

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

INCY

2 minute read

SELLAS Announces Publication Of Preclinical Data On Its Highly Selective CDK9 Inhibitor, SLS009, In Oncotarget

By Benzinga Newsdesk

February 6, 9:38 AM

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

SLS

2 minute read

BioMarin To Present ROCTAVIAN Data Highlighting Long-Term Durability At 2024 European Association For Haemophilia And Allied Disorders Congress

By Benzinga Newsdesk

February 6, 9:36 AM

New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic Benefit for Adults with Severe Hemophilia ASAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global

BMRN

2 minute read

Investors Cheer Highly Awaited Eli Lilly Earnings, Q4 Performance Surpass Expectations Thanks To Strong Zepbound Launch, Surging Weight loss Drug Sales

By Vandana Singh

February 6, 9:29 AM

Eli Lilly beats Q4 2023 revenue expectations at $9.35 billion, driven by higher realized prices and strong sales of Mounjaro, Verzenio, and Jardiance.

LLY

2 minute read

MiNK Therapeutics’ AgenT-797 Presents Results In The Treatment Of Severe Acute Respiratory Distress, Published In Nature Communications

By Benzinga Newsdesk

February 6, 9:17 AM

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell

INKT

1 minute read

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit Of SRK-439 For Healthy Weight Loss Management

By Benzinga Newsdesk

February 6, 9:15 AM

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolismScholar Rock's novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading

SRRK